| Interactions between Xenobiotics and DME (XEOTIC)
|
| Health or Environmental Toxicant(s) |
| Acute Toxic Substance |
Click to Show/Hide the Full List of Xenobiotics: 2 Xenobiotics
|
| Cadmium |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01503
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Acute Toxic Substance |
| DME Modulation |
Cadmium up-regulates the expression of DME CDA |
[1] |
| Formaldehyde |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01305
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Acute Toxic Substance |
| DME Modulation |
Formaldehyde up-regulates the expression of DME CDA |
[2] |
| Carcinogen |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Aflatoxin B1 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00806
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Carcinogen-mycotoxin |
| DME Modulation |
Aflatoxin B1 up-regulates the expression of DME CDA |
[3] |
| Health Hazard/Toxicant |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Tris(1,3-dichloro-2-propyl)phosphate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01031
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Health Hazard |
| DME Modulation |
Tris(1,3-dichloro-2-propyl)phosphate induces the drug-metabolizing activity of DME CDA |
[4] |
| Natural Product(s), Extract(s) or Medicine(s) |
| Traditional Medicine |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Jinfukang |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00760
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Traditional Medicine |
| DME Modulation |
Jinfukang up-regulates the expression of DME CDA |
[5] |
| Pharmaceutical Agent(s) |
| Approved/Marketed Drug |
Click to Show/Hide the Full List of Xenobiotics: 7 Xenobiotics
|
| Calcitriol |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00184
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Calcitriol up-regulates the expression of DME CDA |
[6] |
| Copper sulfate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00117
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Copper sulfate up-regulates the expression of DME CDA |
[7] |
| Crizotinib |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00195
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Crizotinib inhibits the drug-metabolizing activity of DME CDA |
[8] |
| Cyclosporine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00241
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cyclosporine up-regulates the expression of DME CDA |
[9] |
| Isotretinoin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00186
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Isotretinoin inhibits the expression of DME CDA |
[10] |
| Valproic acid |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00029
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Valproic acid up-regulates the expression of DME CDA |
[11] |
| Vitamin D |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00747
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Vitamin D up-regulates the expression of DME CDA |
[12] |
| Drug in Phase 2 Clinical Trial |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| MS-275 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00581
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 2 |
| DME Modulation |
MS-275 up-regulates the expression of DME CDA |
[13] |
| Drug in Phase 1 Clinical Trial |
Click to Show/Hide the Full List of Xenobiotics: 2 Xenobiotics
|
| EP-101 |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00600
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
EP-101 inhibits the drug-metabolizing activity of DME CDA (IC50 = 0.113 microM) |
[14] |
| Quercetin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00538
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
Quercetin induces the drug-metabolizing activity of DME CDA |
[15] |
| Preclinical/Patented Drug |
Click to Show/Hide the Full List of Xenobiotics: 3 Xenobiotics
|
| (+)-JQ1 |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00723
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
(+)-JQ1 inhibits the expression of DME CDA |
[16] |
| Gardiquimod |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00722
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
Gardiquimod inhibits the expression of DME CDA |
[17] |
| Tripterine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00706
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
Tripterine up-regulates the expression of DME CDA |
[13] |
|
|
|
|
|
|